Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million

Posted: December 27, 2022 at 1:11 am

KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced the completion of its public offering of 4,764,674 Series J common shares (“Public Offering”).

Read this article:
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million

Related Posts